Stopped: Due to the ongoing conflict in the Tigray region
In this cohort study, the investigators will study the asymptomatic period preceding the onset of active Visceral Leishmaniasis (VL) in HIV-infected individuals from VL endemic regions in Ethiopia as an avenue to develop an evidence-based screen and treat strategy to prevent progression to active VL.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Prevalence of asymptomatic Leishmania infection
Timeframe: January 2018
Incidence rate of asymptomatic Leishmania infection
Timeframe: January 2020
Evolution of Leishmania infection markers
Timeframe: January 2020
Incidence rate of active VL
Timeframe: January 2020
Risk factors for active VL
Timeframe: January 2020
Prognostic tool for active VL
Timeframe: January 2021